5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a Potent Inhibitor for Mammalian Elongase of Long-Chain Fatty Acids Family 6: Examination of Its Potential Utility as a Pharmacological Tool
Open Access
- 9 April 2009
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 330 (1), 249-256
- https://doi.org/10.1124/jpet.109.150854
Abstract
Long-chain fatty acid elongases reside in the endoplasmic reticulum and are responsible for the rate-limiting step of the elongation of long-chain fatty acids. The elongase of long-chain fatty acids (ELOVL) family 6 (ELOVL6) is involved in the elongation of saturated and monosaturated fatty acids. Increased expression of ELOVL6 in ob/ob mice suggests a role for ELOVL6 in metabolic disorders. Furthermore, ELOVL6-deficient mice are protected from high-fat diet-induced insulin resistance, which suggests that ELOVL6 might be a new therapeutic target for diabetes. As reported previously, we developed a high-throughput screening system for fatty acid elongases and discovered lead chemicals that possess inhibitory activities against ELOVL6. In the present study, we examined in detail the biochemical and pharmacological properties of 5,5-dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione (Compound-A), a potent inhibitor of ELOVL6. In in vitro assays, Compound-A dose-dependently inhibited mouse and human ELOVL6 and displayed more than 30-fold greater selectivity for ELOVL6 over the other ELOVL family members. In addition, Compound-A effectively reduced the elongation index of fatty acids of hepatocytes, suggesting that Compound-A penetrates the cell wall and inhibits ELOVL6. More importantly, upon oral administration to mice, Compound-A showed high plasma and liver exposure and potently reduced the elongation index of the fatty acids of the liver. This is the first study to report a potent and selective inhibitor of mammalian elongases. Furthermore, Compound-A seems to be a useful tool to further understand the physiological roles of ELOVL6 and to evaluate the therapeutic potential of an ELOVL6 inhibitor.Keywords
This publication has 35 references indexed in Scilit:
- Identification of a Lipokine, a Lipid Hormone Linking Adipose Tissue to Systemic MetabolismCell, 2008
- Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesityJournal of Lipid Research, 2006
- Probing the role of stearoyl-CoA desaturase_1 in hepatic insulin resistanceJCI Insight, 2006
- Platensimycin is a selective FabF inhibitor with potent antibiotic propertiesNature, 2006
- Long-chain acyl-CoA esters inhibit phosphorylation of AMP-activated protein kinase at threonine-172 by LKB1/STRAD/MO25American Journal of Physiology-Endocrinology and Metabolism, 2005
- Stearoyl-CoA Desaturase 1 Gene Expression Is Necessary for Fructose-mediated Induction of Lipogenic Gene Expression by Sterol Regulatory Element-binding Protein-1c-dependent and -independent MechanismsPublished by Elsevier BV ,2004
- Sterol Regulatory Element-binding Protein-1 Is Regulated by Glucose at the Transcriptional LevelPublished by Elsevier BV ,2000
- Role of tyrosyl and arginyl residues in rat liver microsomal stearylcoenzyme A desaturaseBiochemistry, 1978
- The enzymic chain elongation of fatty acids by rat-liver microsomesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1965
- The Determination of Enzyme Dissociation ConstantsJournal of the American Chemical Society, 1934